Abstract: Objective The aim of this study was to investigate impact of intravenous somatostatin and omeprazole treatment on hepatic venous pressure gradient (HVPG) in patients with hepatitis B-induced liver cirrhosis (LC) and esophagogastric variceal bleeding (EVB) after endoscopic variceal ligation (EVL). Methods 76 consecutive patients with hepatitis B-induced LC and complicated EVB were encountered in our hospital between January 2022 and January 2025, were randomly assigned to underwent EVL in 38 cases in control, or to receive intravenous somatostatin and omeprazole treatment after EVL in another 38 cases in observation. The free pressure and wedge pressure of hepatic vein were detected by jugular vein puncture, and HVPG was calculated. Serum malondialdehyde, cortisol and C-reactive protein (CRP) levels were detected by ELISA. Results Blood transfusion volume, hemostasis time, incidence of re-bleeding at 72 hours and hospital stay in the observation group were(2.1±0.4)U, (1.8±0.7)h, 2.6% and (9.1±2.0)d, all not significantly different as compared to [(2.4±0.5)U, (2.2±0.6)h, 7.9% and (10.8±2.4)d] in the control group (P＜0.05); HVPG in the observation group was (6.6±1.4)mmHg, much lower than [(8.3±1.8)mmHg, P＜0.05] in the control; serum malondialdehyde, cortisol and CRP levels were(30.1±5.2)U/L, (264.3±15.4)μg/L and (9.7±1.9)mg/L, all significantly lower than [(40.5±6.4)U/L, (297.8±19.1)μg/L and (14.2±3.3)mg/L, respectively, P＜0.05] in the control group. Conclusion The maintained intravenous administration of somatostatin and omeprazole after EVL might decreased HVPG, which might decrease the risk of re-bleeding in patients with LC and EVB.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Endoscopic variceal ligation, Hepatic venous pressure gradient, Somatostatin, Octreotide, Treatment